Schreiner MediPharm, a Germany-based global provider of functional label solutions for the healthcare industry, is introducing a new protective syringe label suitable for deep-freeze applications. The Freeze-Light-Protect syringe label combines light protection with viability at temperatures well below zero and is particularly relevant for sensitive mRNA-based substances as well as cell and gene therapies.
 
The novel active ingredients for mRNA substances and cell and gene therapies entail special logistical challenges, including the need to be transported and stored on dry ice at freezing temperatures as low as -100 °C. Additionally, special light protection is frequently required, depending on the type of substance. 
 
Freeze-Light-Protect is designed to securely adhere to the syringe despite extremely low temperatures, enabling reliable marking. The specialty label also can be enhanced with a variety of UV and light protection levels. The first level provides UV protection exclusively, while a second protects against UV rays and blue light. A third level delivers comprehensive light protection. Light protection levels can be customized to suit the specific requirements of the active ingredient. 
 
Additional integrated functionalities also are available, including detachable documentation labels for vaccination cards or patients’ medical records; inspection windows for checking syringe contents in unadulterated color; and graduations for correct dosing of injections. 
 
The label was developed with partner SCHOTT Pharma, which launched the SCHOTT TOPPAC freeze syringe. The 1 ml long COC syringe was developed for medicines with temperatures down to -100 °C, with a view to retaining the syringe’s functionality and integrity of the syringe closure, thus securing drug stability. Schreiner MediPharm’s Freeze-Light-Protect was tested specifically for the SCHOTT TOPPAC freeze syringe to prove the reliability of the label-integrated protective functions and other features.